Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History. billion.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

Roots Analysis

JANUARY 28, 2024

Conclusion Owing to the increasing popularity of big data in healthcare domain, there is a huge impact of big data in healthcare market size. Throughout her career, Jayita has contributed to over six syndicate market research reports, covering a wide range of trending domains.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

The Pharma Data

DECEMBER 3, 2020

SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network. Checkpoint kinases play a crucial role in the cellular response to DNA damage. About PharmaEngine (TWO: 4162). PharmaEngine, Inc.

Licensing 52

Licensing Licensing Bioavailability DNA 52

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40